亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors

作者
Yong Jiang Zhou,Zhengcheng Liu,Ao Yu,Ge Zhao,Baojun Chen
出处
期刊:ImmunoTargets and therapy [Dove Medical Press]
卷期号:Volume 13: 813-829 被引量:30
标识
DOI:10.2147/itt.s494670
摘要

In recent years, the combination of immune checkpoint inhibitors (ICIs) with antiangiogenic agents has led to significant breakthroughs in cancer treatment. Such as programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Antiangiogenic therapy plays a pivotal role in normalizing blood vessels and remodeling the tumor immune microenvironment while ICIs not only enhance the host's antitumor immune response by blocking negative regulatory signals but also promote vascular normalization. The communication between the vasculature and immune system enables the combined use of ICIs and antiangiogenic therapy to have a synergistic effect. Clinical research has also demonstrated that this combination therapy can significantly improve the efficacy and survival of patients with various solid tumors, the addition of pembrolizumab to axitinib can significantly improve PFS (15.4 m vs 11.1 m) compared to sunitinib in first-line treatments of advanced renal cell carcinoma (RCC). Bevacizumab is the first approved anti-VEGF monoclonal antibody. Bevacizumab in combination with atezolizumab obtain significant benefit in terms of PFS (6.9 m vs 4.3 m) compared to sorafenib in advanced hepatocellular carcinoma (HCC). In addition, a series of investigations have been conducted in other solid tumors, such as colorectal cancer (CRC). Future research directions include the development of novel antiangiogenic agents and ICIs, the exploration of other combination strategies (eg, with chemotherapy or targeted therapy), and the identification of biomarkers for patient selection and monitoring response to therapy. Additionally, more studies are needed to understand the optimal timing and sequencing of these therapies to maximize patient benefit. This review aims to elucidate the mechanisms of action of ICIs plus antiangiogenic drugs and provide summaries of related clinical trials. Meanwhile, we outline the current challenges faced and future directions, include the identification of biomarkers for patient selection and monitoring response to therapy, particularly highlighting the newer therapy strategies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
呆萌的鞯完成签到,获得积分10
2秒前
金木zzz完成签到,获得积分10
2秒前
萧雨墨发布了新的文献求助200
6秒前
6秒前
llllu完成签到 ,获得积分10
8秒前
深蓝盾狗_凝神定气做好准备完成签到,获得积分10
10秒前
芬芬完成签到 ,获得积分10
11秒前
18秒前
20秒前
22秒前
喻白完成签到,获得积分10
23秒前
萧雨墨发布了新的文献求助20
25秒前
喻白发布了新的文献求助10
25秒前
33秒前
Jun的应助被喻白采纳,获得10
35秒前
NexusExplorer的应助被LLL采纳,获得10
36秒前
40秒前
42秒前
46秒前
LLL完成签到,获得积分10
47秒前
fantasy的应助被科研通管家采纳,获得10
52秒前
52秒前
科研通AI65的应助被科研通管家采纳,获得10
52秒前
LLL发布了新的文献求助10
53秒前
榨菜完成签到 ,获得积分10
54秒前
CAOHOU的应助被萧雨墨采纳,获得10
1分钟前
1分钟前
yao发布了新的文献求助10
1分钟前
七友完成签到 ,获得积分10
1分钟前
渢薃完成签到,获得积分10
1分钟前
踏实的初晴完成签到 ,获得积分10
1分钟前
1分钟前
充电宝的应助被白华苍松采纳,获得10
1分钟前
科研通AI6.3的应助被萧雨墨采纳,获得10
1分钟前
1分钟前
张宝完成签到,获得积分10
1分钟前
1分钟前
1分钟前
科研通AI65的应助被萧雨墨采纳,获得10
1分钟前
淡淡砖家完成签到,获得积分20
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190075
求助须知:如何正确求助?哪些是违规求助? 9577196
关于积分的说明 21851952
捐赠科研通 7788182
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559936
邀请新用户注册赠送积分活动 2482810